Other Stories

Full Video

SK Bioscience releases results from phases 1 and 2 of COVID-19 trial with 99% forming antibodies Updated: 2021-11-05 10:06:20 KST

SK Bioscience has revealed that 99-percent of participants for phases 1 and 2 of its COVID-19 vaccine clinical trials formed antibodies against the virus.
On Friday, the company said that results from both trials showed success after administering doses to 328 participants.
It added that there were no signs of serious adverse effects to the vaccine.
Currently, the company has already begun phase 3 of the trials in South Korea and Vietnam and is waiting to start in other countries in Southeast Asia and Europe.
The announcement added the result is a step closer to having South Korea's first domestically developed vaccine.
Reporter : tkim@arirang.com
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.